Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program
Rhea-AI Summary
Gelteq (NASDAQ:GELS) announced a partnership with the Hong Kong Flag Football Program on Dec 16, 2025 to integrate its gel-based hydration and sports performance formulations into men’s, women’s and youth national team training and competition.
The announcement cites recent regional commercial progress, including a China-focused sales agreement with Shenzhen Mana Health Management that carries minimum annual order commitments of at least USD $1.3 million. Gelteq noted prior adoption across Australia and Asia, including league-wide use on the Professional Pickleball Association’s PPA Tour Australia.
Positive
- Minimum annual orders of at least USD $1.3M from China-focused agreement
- Product integration into Hong Kong men’s, women’s and youth national teams
- Existing commercial adoption across Australia and Asia including PPA Tour Australia
Negative
- None.
News Market Reaction – GELS
In the Dec 16 session, GELS gained 0.11%, reflecting a mild positive market reaction. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | China sales deal | Positive | -0.9% | Three‑year China distribution agreement with minimum order commitments. |
| Dec 05 | Preclinical results | Positive | +5.8% | Preclinical data showing improved oral delivery of poorly soluble drugs. |
| Dec 02 | Investor conference | Positive | +3.9% | CEO presentation at Q4 Investor Summit outlining growth strategy and catalysts. |
| Nov 24 | Preclinical bioavailability | Positive | +20.4% | Positive PK results with 38–45% AUC increase vs leading antihistamine. |
| Oct 23 | Preclinical trial start | Positive | +23.0% | Launch of preclinical animal trial for oily and poorly soluble drugs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive scientific or platform-validation news has often seen strong upside reactions, while commercial or partnership updates have drawn more muted or slightly negative moves.
Over the past two months, Gelteq reported several milestones, including a preclinical trial start on Oct 23, positive preclinical bioavailability data on Nov 24, and further preclinical enhancements on Dec 5, all tied to its gel-based delivery platform and often met with double‑digit gains. A China-focused sales agreement on Dec 9 with at least USD $1.3 million in expected revenue over three years drew a small negative reaction. Today’s Asia flag football partnership continues the theme of expanding commercial adoption in sports and wellness.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Collaboration Combines Growing International Interest in Gelteq’s Sports Science Technology with Rising Interest in Flag Football Ahead of 2028 Summer Olympic Games Debut in Los Angeles
MELBOURNE, Australia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced a new partnership with the Hong Kong Flag Football Program. The partnership will integrate Gelteq’s advanced hydration and sports performance formulations into the training and competition programs of the region’s men’s, women’s, and youth national teams.
The initiative underscores the increasing interest in high-performance programs throughout the region and builds on the recently announced China-focused sales agreement with Shenzhen Mana Health Management Co. Ltd., which includes minimum annual order commitments totalling at least USD
Together, these developments demonstrate the increasing commercial adoption of Gelteq’s proprietary delivery technology across both sports and wellness applications as demand continues to grow across Southeast Asia for convenient, research-driven products that enhance athlete hydration, energy stability and recovery.
Hong Kong’s national teams recently recorded milestone successes at the Asia and Oceania Flag Football Intercontinental Championship, where all three teams secured their first official international victories and represent an important step in the development of American football in the region.
“This collaboration showcases the versatility of our gel-based platform and reinforces our commitment to improving athlete performance through science-driven innovation,” said Nathan Givoni, CEO of Gelteq. “Flag football is expanding rapidly ahead of its debut at the 2028 Summer Olympic Games, and we are proud to support Hong Kong’s athletes as they build competitive momentum in Asia.”
Supporting a High-Growth Global Sport
Flag football is one of the fastest-growing team sports internationally, driven by its accessibility, low-contact format, and strong youth and adult participation. Growth in the region is supported by increased investment in sports science and high-performance preparation.
Gelteq’s gel based formulations are designed to support athletes manage hydration, energy regulation, and recovery through a portable, easy-to-administer format. The Company’s technology is already utilised by elite and professional programs across Australia and Asia, including league-wide adoption within the Professional Pickleball Association’s PPA Tour Australia.
“Our platform delivers measurable benefits in environments where athletes need convenience, consistency, and reliable performance support,” Mr. Givoni added. “The Hong Kong partnership demonstrates how our technology can be integrated across national programs and scaled to support both elite and developmental squads.”
Gelteq continues to evaluate additional opportunities across the region as the Company expands its sports product portfolio and advances commercial discussions focused on its proprietary gel-based platform.
About Gelteq Ltd.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq specializes in the formulation, development and manufacturing of gel products for licensed partners across pharmaceutical, consumer health and animal health markets. The proprietary formulation technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit www.gelteq.com.
Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
